

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Casdin Partners Master Fund, L.P.</u> <hr/> (Last) (First) (Middle) 1350 AVENUE OF THE AMERICAS, SUITE 2600 <hr/> (Street) NEW YORK NY 10019 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/04/2022	3. Issuer Name and Ticker or Trading Symbol <u>STANDARD BIOTOOLS INC. [ LAB ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* <u>Casdin Partners Master Fund, L.P.</u> <hr/> (Last) (First) (Middle) 1350 AVENUE OF THE AMERICAS, SUITE 2600 <hr/> (Street) NEW YORK NY 10019 <hr/> (City) (State) (Zip)
---

1. Name and Address of Reporting Person* <u>Casdin Capital, LLC</u> <hr/> (Last) (First) (Middle) 1350 AVENUE OF THE AMERICAS, SUITE 2600 <hr/> (Street) NEW YORK NY 10019 <hr/> (City) (State) (Zip)
---

1. Name and Address of Reporting Person* <u>Casdin Partners GP, LLC</u>
--

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS, SUITE 2600		
<hr/>		
(Street)		
NEW YORK	NY	10019
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

[Casdin Private Growth Equity Fund II, L.P.](#)

---

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS, SUITE 2600		
<hr/>		
(Street)		
NEW YORK	NY	10019
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person\*

[Casdin Private Growth Equity Fund II GP, LLC](#)

---

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS, SUITE 2600		
<hr/>		
(Street)		
NEW YORK	NY	10019
<hr/>		
(City)	(State)	(Zip)

**Explanation of Responses:**

**Remarks:**

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Mr. Casdin files separate Section 16 reports disclosing securities of the Issuer that he may be deemed to beneficially own for Section 16 purposes.

**No securities are beneficially owned.**

[Casdin Partners Master Fund, L.P., By: Casdin Partners GP, LLC, Its: General Partner, By: /s/ Eli Casdin, Its: Managing Member](#) 04/06/2022

[Casdin Capital, LLC, By: /s/ Eli Casdin, Its: Managing Member](#) 04/06/2022

[Casdin Partners GP, LLC, By: /s/ Eli Casdin, Its: Managing Member](#) 04/06/2022

[Casdin Private Growth Equity Fund II, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, By: /s/ Eli Casdin, Its: Managing Member](#) 04/06/2022

[Casdin Private Growth Equity Fund II GP, LLC, By: /s/ Eli Casdin, Its: Managing Member](#) 04/06/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**